Evidence map›Paper›PMID 36299777›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Patterns of Immunohistochemical Expression of P53, BCL2, PTEN, and HER2/neu Tumor Markers in Specific Breast Cancer Lesions.

Mohamed Ahmed Bealy, Awad Aljeed Abugooda, Ruba Mustafa Elsaid Ahmed, Nuha Abdel Rahman Khalil, Abdelbaset Mohamed Elasbali, Ghorashy Eltayeb Yousif Mohamed, Faris Merghani Eltom, Hussain Ahmed

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Mohamed Ahmed BealyDepartment Pathology, College of Medici University of Ha'il-Saudi Arabia, Ha'il, Saudi Arabia.ORCID https://orcid.org/0000-0002-2773-4800
Awad Aljeed AbugoodaDepartment of Histopathology and Cytology FMLS University of Khartoum-Sudan, Khartoum, Sudan.
Ruba Mustafa Elsaid AhmedDepartment Pathology, College of Medici University of Ha'il-Saudi Arabia, Ha'il, Saudi Arabia.ORCID https://orcid.org/0000-0001-8327-7539
Nuha Abdel Rahman KhalilDepartment Pathology, College of Medici University of Ha'il-Saudi Arabia, Ha'il, Saudi Arabia.
Abdelbaset Mohamed ElasbaliClinical Laboratory Science, College of Applied Medical Science- Qurayyat, Jouf University, Qurayyat, Saudi Arabia.ORCID https://orcid.org/0000-0002-7003-9846
Ghorashy Eltayeb Yousif MohamedDepartment Pathology, College of Medici University of Ha'il-Saudi Arabia, Ha'il, Saudi Arabia.ORCID https://orcid.org/0000-0002-0745-0966
Faris Merghani EltomDepartment of Histology, College of Medicine, Alrayan Colleges, Almadinah Almunawwarah, Saudi Arabia.ORCID https://orcid.org/0000-0002-1567-4935
Hussain AhmedDepartment of Histopathology and Cytology FMLS University of Khartoum-Sudan, Khartoum, Sudan.ORCID https://orcid.org/0000-0001-6579-0574
University of Ha'il · SAUniversity of Khartoum · SD

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: This study aimed to associate the expression of P53, BCL2, PTEN, and HER2/neu tumor markers in specific breast cancer lesions. Methods: This study analyzed the immunohistochemical expression of P53, BCL2, PTEN, and HER2/neu tumor markers for 306 patients who presented with lesions. Tissue blocks and patients' identification data were retrieved from the department of pathology, AL Madinah Almonwarah hospital, Al Madinah, UAE. Results: Of the 306 patients, 104 had benign lesions and 202 had malignancy (including 194 females and 6 males). Most females were presented with invasive ductal carcinoma (IDC), followed by infiltrating ductal carcinoma, and invasive lobular carcinoma (ILC), representing 70%, 23.2%, and 3.7%, respectively. Positive P53, BCL2, PTEN, and HER2 were identified in 20.8%, 11.9%, 91%, and 18.3%, respectively. Conclusion: : The expression of P53, BCL2, PTEN, and HER2/neu tumor markers among Saudi patients with breast cancer is relatively similar in many parts of the world.

Identifiers

PMID36299777
PMCPMC9592210
OpenAlexW4306638454

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.